HER2-positive HR-negative breast cancer
Conditions
Interventions
Trastuzumab-containing chemotherapy followed by whole breast irradiation, then surgery.
Chemotherapy is sequential treatment of anthracyclines and taxanes with tarastuzumab or TCH.
Select one of the
AC, EC, FAC, FEC and Dose dense AC
Select one of the following taxane with tarastuzumab regimens
PTX/T-mab and DTX/T-mab
Sponsors
Japan Agency for Medical Research and development
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria:
Exclusion criteria
Exclusion criteria: 1. Active other malignancies 2. Bilateral breast cance 3. Multicentric tumors 4. History of congestive heart failure or myocardial infarction, arrhythmia or heart valvular disease requiring treatment 5. Clinically significant infection 6. Pregnant or breast-feeding women, women of childbearing potential 7. Diabetes uncontrolled or requiring insulin 8. Systemic sclerosis or systemic lupus erythematosus 9. Systemic use of steroids or immunosuppressive agents 10. Unsuitable mental status for participation 11. Ineligible based on decision of an investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pCR rate in HSD17B4-hypermethylated breast cancer | — |
Countries
Japan
Contacts
Public ContactHiromi Shinano
Comprehensive Support Project Oncological Research of Breast Cancer Administration Office
Outcome results
None listed